BHC

Business Context and Reporting Period

Company: Biovail Corporation (formerly Biovail Corporation International)

Filing Type: Form 20-F (Annual Report)

Reporting Period: Fiscal year ended December 31, 1999

Business Overview: Biovail is an international, fully-integrated pharmaceutical company specializing in controlled-release, rapid dissolve, and enhanced absorption drug delivery technologies. The company develops, manufactures, and markets generic and branded pharmaceutical products. It operates through three primary segments: Product Sales, Research and Development (R&D), and Royalty and Licensing. In Canada, products are marketed directly via the Crystaal division; globally, products are marketed through strategic licensing partners.

Key Financial Metrics (Fiscal Year 1999)

Note: The significant discrepancy between Canadian GAAP net income and U.S. GAAP net loss is primarily due to the immediate write-off of $136.2 million in acquired in-process research and development (IPR&D) and $25.0 million in acquired product rights related to the Fuisz Technologies acquisition, which are capitalized under Canadian GAAP.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 56% to $176.5 million from $112.8 million in 1998. This was driven by strong sales of the principal product, Tiazac (44% of total revenue), and the launch of generic versions of Verelan and Cardizem CD.
• Acquisition of Fuisz Technologies: Completed in November 1999 for a total consideration of approximately $259 million (cash, stock, and assumed debt). This acquisition significantly expanded the company's technology portfolio and U.S. manufacturing footprint.
• Product Pipeline: Received tentative FDA approval for generic Adalat CC and full approval for generic Cardizem CD. Acquired rights to generic Procardia XL from Intelligent Polymers for $25 million.
• Capital Structure: Completed a $259 million equity offering in October 1999. In March 2000 (subsequent to year-end), the company issued $300 million in convertible debentures and repurchased $125 million in Senior Notes.
• Segment Performance: R&D revenues grew significantly to $52.3 million (from $32.1 million in 1998) due to increased development activity for Intelligent Polymers and third-party clients.

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management anticipates full integration of Fuisz Technologies operations in 2000. The company expects to report future financial results in accordance with U.S. GAAP. Liquidity is considered adequate to support operations and investment objectives, bolstered by strong cash flows and recent financing activities.

Key Risks and Contingencies:

• Regulatory Approvals: Success depends heavily on FDA and Health Canada approvals for pipeline products. Delays or rejections could materially impact future revenues.
• Patent Litigation: The company is involved in patent infringement suits regarding generic versions of Tiazac, Procardia XL, and Adalat CC. While management believes these will not have a material adverse effect, litigation outcomes are uncertain and could delay product launches.
• Accounting Standards: The transition to U.S. GAAP reporting will result in significant non-cash charges for acquired IPR&D, impacting reported earnings despite strong operational cash flow.
• Concentration Risk: Tiazac accounted for approximately 44% of total revenues in 1999. Forest Laboratories Inc. accounted for 42% of total revenues.

Investor Verification Checklist

• U.S. GAAP Reconciliation: Verify the impact of the $161.2 million write-off (IPR&D and product rights) on future earnings under U.S. GAAP versus the strong Canadian GAAP profitability.
• Fuisz Integration: Assess the timeline and cost of integrating Fuisz Technologies, including potential restructuring costs and the realization of synergies.
• Regulatory Status: Confirm the status of FDA approvals for key pipeline products (Verelan, Procardia XL, Adalat CC) and the resolution of pending patent litigation.
• Debt Obligations: Review the terms of the $300 million convertible debentures issued in March 2000 and the repayment schedule for remaining long-term debt.
• Customer Concentration: Monitor the dependency on Forest Laboratories and Teva Pharmaceuticals, which collectively represent a significant portion of revenue.